A retrospective study in patients with advanced Non-Small Cell Lung Cancer (NSCLC) who received nivolumab, pembrolizumab or atezolizumab monotherapy
Latest Information Update: 18 Oct 2019
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 18 Oct 2019 New trial record
- 10 Sep 2019 Results (n=275) presented at the 20th World Conference on Lung Cancer.